Suzanne George

Has grant

Harvard University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Validation of predictive and prognostic biomarkers in patients with post-chemotherapy residual disease in A011202

Open Date: 2022-10-01

Close Date: 2024-09-30

Grant: Close

Clonal Hematopoiesis of Indeterminate Potential (CHIP), Obesity, and Breast Cancer Outcomes in the Breast Cancer Weight Loss (BWEL) Trial

Open Date: 2021-10-01

Close Date: 2023-09-30

Articles (50)

Year:

2026

Year:

2026

Year:

2025

Purpose: Cardiac angiosarcoma is a rare, aggressive malignancy with limited treatment options. Both sporadic and familial cases occur, with recent links to germline POT1 mutations. The genomic landscape of this disease is poorly understood. Experimental Design: We conducted comprehensive genomic profiling of cardiac angiosarcoma to assess the burden of germline predisposition and identify other recurrent genomic alterations of clinical significance. Results: Six patients were female, and four were male. The median age at presentation was 40 years (range, 21–69 years). All cases with available follow-up exhibited an aggressive clinical course (6/8 patients died of disease). KDR alterations, including novel structural variants, were found in 9/11 cases at a rate significantly higher than that in noncardiac angiosarcomas. POT1 mutations were present in 45.5% of cardiac angiosarcoma cases. In three of five POT1-mutant cases, the germline status was confirmed through testing of normal tissue, and in one additional case, the germline status was inferred with high probability through allele frequency analysis. Additionally, we identified novel recurrent MED12 exon 2 mutations in POT1 wild-type cardiac angiosarcoma, suggesting an alternative path to cardiac angiosarcoma oncogenesis. Conclusions: Cardiac angiosarcoma demonstrates a unique genetic profile, distinct from noncardiac angiosarcoma. This study highlights the role of germline POT1 burden on cardiac angiosarcoma development and demonstrates recurrent MED12 alterations for the first time. The reported KDR variants provide a potential avenue for the treatment of this aggressive disease. Given the prevalence of germline POT1 mutations reported in this study, germline genetic testing should be considered in patients diagnosed with cardiac angiosarcoma.

Year:

2025

GI stromal tumors (GISTs) are mesenchymal neoplasms with variable natural histories, originating in the GI tract, most commonly in the stomach. They are frequently characterized by KIT or platelet-derived growth factor receptor alpha ( PDGFRA ) oncogenic mutations. Surgical resection remains the cornerstone treatment for localized GISTs. Clinical trials have demonstrated the benefits of adjuvant imatinib in patients selected on the basis of recurrence risk and gene mutations, although the optimal duration of therapy is yet to be established. Some data suggest that longer durations of adjuvant imatinib (>3 years) may provide additional benefit, which is being investigated in ongoing trials. Management of imatinib-related adverse effects is essential during treatment, and longitudinal abdominal imaging is mandatory both during and after adjuvant therapy. Once GISTs are more advanced and unresectable, KIT- and PDGFRA-directed tyrosine kinase inhibitors (TKIs) become the key treatment in most patients with KIT mutation. Several TKIs have regulatory approval for advanced GISTs, but in most patients, resistance to TKIs eventually emerges, mainly from secondary resistance mutations in KIT . Each TKI has different coverage of oncogenic KIT mutations, suggested by preclinical and clinical findings, which has given rationale to an ongoing clinical trial that includes molecular selection as eligibility criteria. Furthermore, novel treatment approaches, from TKI combinations to an antibody-drug conjugate, are being investigated. Despite the significant advance in managing GISTs with KIT mutations, those without KIT or PDGFRA mutation, which consists of 10%-15% of patients with GIST, can be a clinical challenge in the advanced setting. These non- KIT/PDGFRA GISTs could be driven by genomic or epigenomic alterations in SDHx , NF1 mutations, and other genomic alterations. Non- KIT/PDGFRA GISTs are less responsive to currently available TKIs than GISTs driven by KIT/PDGFRA mutations, and each subset of non- KIT/PDGFRA GIST has distinctive biology and clinical features. Therefore, individualized, multidisciplinary, biology-based management and consideration for clinical trial enrollment are critical for non- KIT/PDGRFA GISTs.

Year:

2025

Supplementary Table S3: List of pathogenic or likely pathogenic mutations in LMS based on 1) ClinVar (20); 2) functional classification as deleterious by both SIFT (21) and PolyPhen (22); and 3) truncating nature of the mutation.

Year:

2025

Supplementary Figure S6 Representative cell culture images of LMS04 cultures untreated or treated with 2nM doxorubicin, 400 nM peposertib, or the combination of both, utilized for computationally assisted cell culture confluence analysis (See Supplementary Figure S7).

Year:

2025

Supplementary Figure S3: Mutated genes, fraction and counts of non-structural mutations in each gene (right) in clinical samples from 251 LMS tumors sequenced with OncoPanel. A. Alterations in TP53, RB1 and ATRX were detected in 73%, 73% and 31% of LMS, respectively, including single copy deletions and low amplitude gains; B. Alterations in genes mutated in >4% of samples, excluding single copy deletions and low amplitude gains. Deleterious mutations impacting BRCA2 or BRCA1 were demonstrated in 49% of LMS and were most often heterozygous deletions, whereas 8% of LMS had identifiable BRCA1/BRCA2 intragenic mutations or homozygous deletions. As with other targeted NGS platforms, these findings underestimate the true frequency of TP53 and RB1 mutations, given challenges detecting inactivating structural variants, particularly in large genes such as RB1.

Year:

2025

Supplementary Figure S8: Synergistic effects of peposertib and low-dose doxorubicin combinations in LMS cells. Cell proliferation assay (BrdU incorporation) demonstrates that addition of low-dose doxorubicin to DNA-PKi treatment results in synergistic effects on LMS03, LMS04 and LMS05 cell proliferation. Cells were treated for 7 days with the drug combinations at the indicated doses; BrdU incorporation over 24h was measured at day 7 with a luminescence-based ELISA assay (Roche). Synergy scores and heatmap / surface plots were generated using SynergyFinder (RRID:SCR_019318)(35).

Year:

2025

Supplementary Figure S1: A. Fraction of genome altered (FGA) in non-LMS cancers compared to LMS from GENIE v9.0 (37). B. FGA in LMS and in other tumor types in the GENIE dataset, including high grade sarcomas.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (39)

Heikki Joensuu

University of Helsinki

FINLAND
View details

Karla Ballman

Chair / Consultant / Professor of Biostatistics

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Sandro Santagata

Brigham and Women's Hospital

UNITED STATES
View details

Frank Tadashi Zenke

Chief Scientific Officer

-

SWITZERLAND
View details

Julia Glade Bender

Vice Chair for Clinical Research

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Neeta Somaiah

Professor and Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Douglas Hawkins

Professor

University of Washington

UNITED STATES
View details

Michael Wagner

Dana-Farber Cancer Institute

UNITED STATES
View details

Thierry Alcindor

McGill University Health Centre

CANADA
View details

Igor Odintsov

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Lori Rink

Associate Professor

Fox Chase Cancer Center

UNITED STATES
View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES
View details

Peter Park

Harvard University

UNITED STATES
View details

Yoon-Koo Kang

Professor

Asan Medical Center

SOUTH KOREA
View details

Margaret von Mehren

Professor

Fox Chase Cancer Center

UNITED STATES
View details

jordan Berlin

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

James Ford

Professor

Stanford University

UNITED STATES
View details

Joseph Michael Unger

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Eric Tetzlaff

Physician Assistant, Assistant Professor

Fox Chase Cancer Center

UNITED STATES
View details

Gary Lyman

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Jason Sicklick

University of California, San Diego

UNITED STATES
View details

Robert Gray

Dana-Farber Cancer Institute

UNITED STATES
View details

John R. Zalcberg

-

AUSTRALIA
View details

Melissa Burgess

University of Pittsburgh

UNITED STATES
View details

Gabriel Tinoco

Associate Professor of Medicine

Ohio State University

UNITED STATES
View details

Petros Grivas

University of Washington

UNITED STATES
View details

Robert G. Maki

Professor, Member

-

UNITED STATES
View details

Peter Sorger

Otto Krayer Professor of Systems Pharmacology

Harvard Medical School

UNITED STATES
View details

Robin Jones

Consultant Medical Oncology, Head of Sarcoma Unit

Royal Marsden NHS Foundation Trust

UNITED KINGDOM
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Michael C. Heinrich

Oregon Health & Science University

UNITED STATES
View details

Hans Gelderblom

Prof.dr

Leiden University Medical Center

NETHERLANDS
View details

Sebastian Bauer

Professor / Chair

Universität Duisburg-Essen

GERMANY
View details

Cesar Serrano

External Group Leader (TRIP-Clinic program)

IRB Barcelona

SPAIN
View details

Jean-Yves Blay

University Professor, Medical Oncology

Université Claude Bernard Lyon 1 - Domaine de Rockefeller

FRANCE
View details

Elizabeth Davis

Vanderbilt University Medical Center

UNITED STATES
View details

Edwin Choy

Associate Professor

Harvard Medical School

UNITED STATES
View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elizabeth Handorf

Associate Professor

Rutgers, The State Univ. of NJ

UNITED STATES
View details